Paediatric healthcare and hospital worker SARS-CoV-2 IgG antibody: A longitudinal cohort study

•Paediatric hospital setting.•Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) immunoglobulin G (IgG) nucleocapsid protein antibodies were detected in 1.9% of healthcare and hospital workers (HCHWs).•SARS-CoV-2 IgG spike protein antibodies were detected in 97.6% of HCHWs.•Low hospital tr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:IJID regions 2023-06, Vol.7, p.281-286
Hauptverfasser: Cappetto, Kaitlin D., Brown, Julie C., Englund, Janet A., Zerr, Danielle M., Dickerson, Jane A., Wang, Xing, Strelitz, Bonnie, Klein, Eileen J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•Paediatric hospital setting.•Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) immunoglobulin G (IgG) nucleocapsid protein antibodies were detected in 1.9% of healthcare and hospital workers (HCHWs).•SARS-CoV-2 IgG spike protein antibodies were detected in 97.6% of HCHWs.•Low hospital transmission of SARS-CoV-2 with infection prevention measures. This study sought to determine the prevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) nucleocapsid (N) and spike (S) protein immunoglobulin G (IgG) antibodies in healthcare and hospital workers (HCHWs), and changes in IgG N antibody levels over time. Longitudinal study of HCHWs at a freestanding, urban paediatric tertiary care hospital. Asymptomatic HCHWs aged ≥18 years working in clinical areas were eligible to enrol. Participants completed four surveys and blood draws over 12 months. Specimens were tested for IgG N at four timepoints and IgG S at 12 months. In total, 531 HCHWs enrolled in this study; of these, 481 (91%), 429 (81%) and 383 (72%) completed follow-up blood draws at 2, 6 and 12 months, respectively. Five of 531 (1%), 5/481 (1%), 6/429 (1%) and 5/383 (1.3%) participants were seropositive for IgG N at baseline, 2, 6 and 12 months, respectively. All (374/374; 100%) participants who received one or two doses of either mRNA COVID-19 vaccine were seropositive for IgG S. One of nine unvaccinated participants was seropositive for IgG S. In this paediatric hospital, IgG N and IgG S were detected in 1.9% and 97.9% of HCHWs, respectively. This study demonstrated low transmission of SARS-CoV-2 among HCHWs with appropriate infection prevention measures.
ISSN:2772-7076
2772-7076
DOI:10.1016/j.ijregi.2023.05.001